Applied Information Aspects of Medicine (Prikladnye informacionnye aspekty mediciny)Applied Information Aspects of Medicine (Prikladnye informacionnye aspekty mediciny)2070-9277Voronezh State Medical University named after N.N. Burdenko - The State Budgetary Institution of Higher Professional Education «Voronezh State Medical University named after N.N. Burdenko» of the Ministry of Public Health of the Russian932110.18499/2070-9277-2023-26-4-%pBiomarkers and biochemical parameters of venous blood as criteria for the effectiveness of SARS-CoV-2 therapy with intracellular non-receptor tyrosine kinasesKostenkoStanislav Mkostenko@aidsvrn.ruTulinovaIrina Atulinova@aidsvrn.ruAndreiasSergei Vz_org@aidsvrn.ruDushkinaNatalya Vz_med@aidsvrn.ruMuhaTatyana Amuha@aidsvrn.ruZotovaElena Еzotova1109@yandex.ruKostenkoДмитрий Sdmitrij2012@yandex.ru29122023264899508022024Copyright © 2023, Applied Information Aspects of Medicine (Prikladnye informacionnye aspekty mediciny)2023<p>Severe acute respiratory syndrome associated with coronavirus-2 (SARS-CoV-2) is a systemic disease characterized by various severity of pulmonary symptoms, cardiac conduction disorders, gastrointestinal disorders, as well as neurological and endocrine disorders, renal insufficiency, myalgia. SARS-CoV-2 infection contributes to the imbalance between innate and adaptive immunity, which becomes more pronounced, especially in patients with severe form. Its effect on the pancreas, liver and other organs may be due to both direct cytopathic action and immuno-mediated mechanisms. The pathological effect of this virus on lipid metabolism and the blood coagulation system has been proven. Excessive and uncontrolled release of pro-inflammatory cytokines, characteristic of a new coronavirus infection, contributes to the development of a "cytokine storm". Janus kinase inhibitors have been proposed as a new type of immunomodulatory drugs. With a new coronavirus infection, these drugs can prevent the development of a "cytokine storm".</p>new coronavirus infection, dysfunction of the liver and pancreas, lipid metabolism, blood clotting systemновая коронавирусная инфекция, нарушение функции печени, глюкоза крови, липидный обмен, свертывающая система крови.1. Wu CT, Lidsky PV, Xiao Y, Lee IT, Cheng R, Nakayama T, et al. SARSCoV-2 infects human pancreatic beta cells and elicits beta cell impairment. Cell Metab. 2021;33(8):1565–76.2. Steenblock C, Richter S, Berger I, Barovic M, Schmid J, Schubert U, et al. Viral infiltration of pancreatic islets in patients with COVID-19. Nat Commun. 2021;12(1):3534.3. Tang X, Uhl S, Zhang T, Xue D, Li B, Vandana JJ, et al. SARS-CoV-2 infection induces beta cell transdifferentiation. Cell Metab. 2021;33(8):1577–91.4. Srivastava A, Rockman-Greenberg C, Sareen N, Lionetti V, Dhingra S. An insight into the mechanisms of COVID-19, SARS-CoV2 infection severity concerning beta-cell survival and cardiovascular conditions in diabetic patients. Mol Cell Biochem. 2022;477(6):1681–95.5. Cichoż-Lach H, Michalak A. Liver injury in the era of COVID-19. World J Gastroenterol 2021; 27(5): 377-390.6. Wei, X.; Zeng, W.; Su, J.; Wan, H.; Yu, X.; Cao, X.; Tan, W.; Wang, H. Hypolipidemia is associated with the severity of COVID-19. J. Clin. Lipidol. 2020, 14, 297–304.7. Hu, X.; Chen, D.;Wu, L.; He, G.; Ye,W. Declined serum high density lipoprotein cholesterol is associated with the severity of COVID-19 infection. Clin. Chim. Acta 2020, 510, 105–110.8. Sun, J.T.; Chen, Z.; Nie, P.; Ge, H.; Shen, L.; Yang, F.; Qu, X.L.; Ying, X.Y.; Zhou, Y.;Wang,W.; et al. Lipid Profile Features and Their Associations with Disease Severity and Mortality in Patients With COVID-19. Front. Cardiovasc. Med. 2020, 7, 584987.9. Jean M.Connor, Jerrold H.Levy. COVID-19 and its implications for thrombosis and anticoagulation. Blood 4 JUNE 2020 | VOLUME 135, NUMBER 2310. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18:844–847.11. Zegeye M.M., L. Madelene, F. Knut, et al., Activation of the JAK/STAT3 and PI3K/ AKT pathways are crucial for IL-6 trans-signaling-mediated pro-inflammatory response in human vascular endothelial cells, Cell Commun. Signal. 16 (1) (2018) 55.12. O'Shea J.J., Schwartz D.M., Villarino A.V., et al., The JAK-STAT pathway: impact on human disease and therapeutic intervention, Annu. Rev. Med. 66 (2015) 311–328.13. Taylor P.C., Keystone E.C., Désirée van der Heijde, et al., Baricitinib versus placebo or adalimumab in rheumatoid arthritis, N. Engl. J. Med. 376 (7) (2017) 652–662.14. Gadina M., Johnson C., Schwartz D., et al., Translational and clinical advances in JAK-STAT biology: the present and future of jakinibs, J. Leukoc. Biol. 104 (3) (2018) 499–514.15. Bronte Vincenzo, Ugel Stefano, Tinazzi Elisa Baricitinib restrains the immune dysregulation in patients with severe COVID-19 J Clin Invest. 2020;130(12):6409-6416.16. Tanaka Yoshiya, Luo Yiming, John J. O’Shea, Shingo Nakayamada Janus kinase-targeting therapiesin rheumatology: a mechanisms-based approach. Nat Rev Rheumatol 18, 133-145 (2022).